BriaCell Therapeutics (TSX:BCT) Beginning Cash Position : C$18.32 Mil (As of Jan. 2024)

View and export this data going back to 2006. Start your Free Trial

What is BriaCell Therapeutics Beginning Cash Position?

BriaCell Therapeutics's Beginning Cash Position for the quarter that ended in Jan. 2024 was C$18.32 Mil.

BriaCell Therapeutics's quarterly Beginning Cash Position declined from Jul. 2023 (C$37.22 Mil) to Oct. 2023 (C$29.14 Mil) and declined from Oct. 2023 (C$29.14 Mil) to Jan. 2024 (C$18.32 Mil).

BriaCell Therapeutics's annual Beginning Cash Position increased from Jul. 2021 (C$0.03 Mil) to Jul. 2022 (C$74.08 Mil) but then declined from Jul. 2022 (C$74.08 Mil) to Jul. 2023 (C$54.22 Mil).

BriaCell Therapeutics Beginning Cash Position Historical Data

The historical data trend for BriaCell Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Beginning Cash Position Chart

BriaCell Therapeutics Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Beginning Cash Position

Get a 7-Day Free Trial

1.00

0.21

0.03

74.08

54.22

BriaCell Therapeutics Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Beginning Cash Position	Get a 7-Day Free Trial															50.27	45.17	37.22	29.14	18.32

BriaCell Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

BriaCell Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics (TSX:BCT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

BCTX:USA

Address

235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

Executives

Jamieson Bondarenko

Director

BriaCell Therapeutics (TSX:BCT) Headlines

No Headlines